Digoxin: Its role in contemporary medicine

Postgraduate Medical Journal

Volumn 91, Issue 1079, 2015, Pages 514-518

  Stucky, Marcelle A ^a   Goldberger, Zachary D ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) INHIBITOR; AMIODARONE; DIGOXIN; ERYTHROMYCIN; LOOP DIURETIC AGENT; QUINIDINE; RIFAMPICIN; TETRACYCLINE; CARDIOTONIC AGENT;

ATRIOVENTRICULAR CONDUCTION; CALCIUM CELL LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ELECTROCARDIOGRAM; EVIDENCE BASED MEDICINE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HUMAN; HYPERCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; MULTICENTER STUDY (TOPIC); RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SARCOPLASMIC RETICULUM; TACHYCARDIA; VAGUS TONE; DRUG INTERACTION; HISTORY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

CARDIOTONIC AGENTS; DIGOXIN; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; HEART FAILURE; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HISTORY, ANCIENT; HUMANS; RETROSPECTIVE STUDIES; TACHYCARDIA; TREATMENT OUTCOME;

EID: 84940893636     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2014-132937     Document Type: Review

References (42)

1. Tellingen CV. Pliny’s pharmacopoeia or the Roman Treat. Neth Heart J 2007;15:118–20.
2. Hollman A. Plants in cardiology: medicinal plant discovery. Br Heart J 1992;67:506.
3. Ventura HO, Mehra MR. Bloodletting as a cure for dropsy: heart failure down the ages. J Card Fail 2005;11:247–52.
4. Withering W. An account of the foxglove and some of its medicinal uses: with practical remarks on dropsy, and other diseases. Birmingham, England: M. Swinney, 1785.
5. Falk RH, Leavitt JI. Digoxin for atrial fibrillation: a drug whose time has gone? Ann Intern Med 1991;114:573–5.
6. Hauptman PJ, Kelly RA. Digitalis. Circulation 1999;99:1265–70.
7. Maron BA, Rocco TP. Chapter 28. Pharmacotherapy of Congestive Heart Failure. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman’s the pharmacological basis of therapeutics, 12e. New York, NY: McGraw-Hill, 2011. http://accessmedicine.mhmedical.com.offcampus.lib.washington.edu/content.aspx?bookid=374&Sectionid=41266235 (accessed 10 Oct 2014).
8. Ferguson DW, Berg WJ, Sanders JS, et al. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation 1989;80:65–77.
9. Demiryurek AT, Demiryurek S. Cardiotoxicity of digitalis glycosides: roles of autonomic pathways, autacoids and ion channels. Auton Autacoid Pharmacol 2005;25:35–52.
10. Smith TW, Butler VP Jr, Haber E. Determination of therapeutic and toxic serum digoxin concentrations by radioimmunoassay. N Engl J Med 1969;281:1212–6.
11. Uretsky BF, Young JB, Shahidi E, et al. on behalf of the PROVED Investigative Group. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol 1993;22:955–62.
12. Packer M, Gheorghiade M, Young JB, et al., for the RADIANCE study. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. N Engl J Med 1993;329:1–7.
13. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525–33.
14. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003;289:871–8.
15. Goldberger ZD, Goldberger AL. Therapeutic ranges of serum digoxin concentrations in patients with heart failure. Am J Cardiol 2012;109:1818–21.
16. Hauptman PJ, McCann P, Romero JM, et al. Reference laboratory values for digoxin following publication of Digitalis Investigation Group (DIG) trial data. JAMA Intern Med 2013;173:1552–4.
17. Bhatia SJ. Digitalis toxicity—turning over a new leaf? West J Med 1986;145:74.
18. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999;104:147.
19. Katoh M, Nakajima M, Yamazaki H, et al. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci 2001;12:505.
20. Hager WD, Fenster P, Mayersohn M, et al. Digoxin-quinidine interaction pharmacokinetic evaluation. N Engl J Med 1979;300:1238–41.
21. Singh BN. Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy. Clin Cardiol 1997;20:608–18.
22. Radford DJ, Gillies AD, Hinds JA, et al. Naturally occurring cardiac glycosides. Med J Aust 1986;144:540–4.
23. Goldberger ZD. ECG image of the month. Withering away. Am J Med 2008;121:1052–4.
24. Gorgels APM, Vos MA, Smeets JLRM, et al. Delayed afterdepolarizations and atrial and ventricular arrhythmias. In: Rosen MR, Janse MJ, Wit AL, eds. Cardiac electrophysiology: a textbook. Mount Kisco: Futura Publishing, 1990:341.
25. Steinbeck G, Bonke FI, Allessie MA, et al. The effect of ouabain on the isolated sinus node preparation of the rabbit studied with microelectrodes. Circ Res 1980;46:406.
26. Ma G, Brady WJ, Pollack M, et al. Electrocardiographic manifestations: digitalis toxicity. J Emerg Med 2001;20:145.
27. Kelly RA, Smith TW. Recognition and management of digitalis toxicity. Am J Cardiol 1992;69:108G.
28. Budnitz DS, Lovegrove MC, Shehab N, et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011;365:2002–12.
29. Haynes K, Heitjan D, Kanetsky P, et al. Declining public health burden of digoxin toxicity from 1991 to 2004. Clin Pharmacol Ther 2008;84:90–4.
30. Gandhi AJ, Vlasses PH, Morton DJ, et al. Economic impact of digoxin toxicity. Pharmacoeconomics 1997;12:175–81.
31. Goldberger ZD, Alexander GC. Digitalis use in contemporary clinical practice: refitting the foxglove. JAMA Intern Med 2014;174:151–4.
32. Ahmed A, Zile MR, Rich MW, et al. Hospitalizations due to unstable angina pectoris in diastolic and systolic heart failure. Am J Cardiol 2007;99:460–4.
33. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825–33.
34. Gheorghiade M, Fonarow GC, van Veldhuisen DJ, et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J 2013;34:1489–97.
35. Whitbeck MG, Charnigo RJ, Khairy P, et al. Increased mortality among patients taking digoxin-analysis from the AFFIRM study. Eur Heart J 2013;34:1481–8.
36. Turakhia MP, Santangeli P, Winkelmayer WC, et al. Increased mortality associate with digoxin in contemporary patients with atrial fibrillation: Findings from the TREAT-AF Study. J Am Coll Cardiol 2014;64:660–8.
37. Freeman JV, Reynolds K, Fang M, et al. Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study. Circ Arrhythm Electrophysiol 2015;8:49–58.
38. Shah M, Tsadok MA, Jackevicius CA, et al. Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients ≥65 years of age with versus without heart failure. Am J Cardiol 2014;114:401–6.
39. McMurray JJ, Adamopoulos S, Anker SD, et al., Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology: developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803–69.
40. Yancy CW, Jessup M, Bozkurt B, et al., ACCF/AHA Task Force Members. 2013 ACCF/AHA Guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147–239.
41. Lindenfeld J, Albert NM, Boehmer JP, et al., Heart Failure Society of America. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010;16:e1–194.
42. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257–354.